In Australia, over 200,000 people live with epilepsy, a chronic neurological condition that is often characterised by seizures. Thousands are hospitalised every year for epilepsy, and even with anti-seizure medication, some people continue to experience mild to severe seizures. Between 2018 and 2019, the condition accounted for over $300 million in national health expenditure. Epilepsy
Read More
Since the easing of regulatory red tape and wider societal acceptance of utilising cannabis for its medical properties, the medicinal cannabis industry has become an intense battleground as researchers have raced towards commercial products. In the case of Cann Group (ASX: CAN) though, they might have just triggered a land mine. Undertaking any form of
Read More
Are investors panic selling their shares at medicinal cannabis company Cronos Australia (ASX: CAU)? With 73.4% of the Company’s shares to be released from voluntary escrow soon, it’s the only explanation Cronos could give to the ASX to explain the irregular trading activity. Cronos, who became Australia’s first ever ASX-listed cannabis company to pay out
Read More
Cannabis is having a major moment these past few years, trending in research and trickling down into the retail sector. Medicinal cannabis company Bod Australia (ASX: BOD) has been selling cannabidiol (CBD) food products within the UK for a while now, however recent legislative changes around the substance dictate that manufacturers now require approval to
Read More
Putting behind them the drama of 2021 which resulted in their former Chairman’s offices being raided by Australian Federal Police, medicinal cannabis company Creso Pharma (ASX: CPH) has kicked off the new year with a bang, confirming their entry into the lucrative US market through the acquisition of Sierra Sage Herbs. Founded in 2008 by
Read More
With rising COVID cases around the world following the latest Omicron strain outbreak, UK regulators are willing to try anything to reduce the mortality rate of COVID-19, including the use of medicinal cannabis for which Bod Australia (ASX: BOD) has been approved to commence clinical trials. The Clinical Trial Authorisation (CTA) has been granted by
Read More